Agomelatine is a novel antidepressant with melatonin MT1/MT2 receptor agonist and serotonin 5-HT2C receptor antagonist properties. Because of its peculiar pharmacological profile, this drug caters the potential to improve both sleep disturbances and depressive symptomatology. At present, about the antidepressant mechanism of agomelatine, researchers mainly focused on it as MT receptor agonist, but ignored that it can also antagonize 5-HT2C receptors. In our prelimiary study, we found that the expression of 5-HT2C receptor mRNA in suprachiasmatic nucleus (SCN) of depressed rats was significantly higher than that of normal rats. Therefore, based on our previous work, we plan to establish a model of depression associated with sleep disorders to detect whether the actions of agomelatine as a 5-HT2C receptor antagonist are located within the SCN, and to investigate the effect and molecular mechanisms. The expected outcome of this study will provide new evidence to help to open new avenues for the discovery of antidepressive agents.
阿戈美拉汀是近年来新上市的一种抗抑郁药物,具有激动褪黑素MT1/MT2受体和拮抗五羟色胺5-HT2C受体的双重作用,其优点在于抗抑郁治疗的同时能有效的调节睡眠障碍。目前关于阿戈美拉汀抗抑郁作用机制的研究,主要集中在MT受体激动剂方面,作为5-HT2C受体拮抗剂的研究较少。本项目拟在我们前期研究发现,慢性温和性刺激获得的抑郁症模型大鼠SCN内5-HT2C受体mRNA表达上调的基础上,利用抑郁症伴睡眠障碍大鼠模型,从5-HT2C受体的角度探讨阿戈美拉汀发挥抗抑郁作用的靶点在SCN,并初步探讨其抗抑郁作用的机制,为抗抑郁药物的研究提供新的思路。
阿戈美拉汀是近年来新上市的一种抗抑郁药物,具有激动褪黑素受体和拮抗五羟色胺5-HT2C受体的双重作用,其优点在于抗抑郁治疗的同时能有效的调节睡眠障碍。目前关于阿戈美拉汀抗抑郁作用机制的研究,主要集中在褪黑素受体激动剂方面,作为5-HT2C 受体拮抗剂的研究较少。本项目拟在我们前期研究发现,慢性温和性刺激获得的抑郁症模型大鼠SCN内5-HT2C受体mRNA表达上调的基础上,采用离体电生理的方法,使用体外大鼠脑切片模型,发现了阿戈美拉汀、褪黑素和选择性5-HT2C受体拮抗剂S32006均能浓度依赖性的抑制SCN神经元放电频率,给予褪黑素受体拮抗剂或5-HT2C受体激动剂能部分逆转阿戈美拉汀的抑制作用,证明了阿戈美拉汀通过作用于褪黑素受体和5-HT2C受体调节SCN神经元活动,为抗抑郁药物的研究提供新的思路。
{{i.achievement_title}}
数据更新时间:2023-05-31
中药对阿尔茨海默病β - 淀粉样蛋白抑制作用的实验研究进展
Enhanced piezoelectric properties of Mn-modified Bi5Ti3FeO15 for high-temperature applications
甘丙肽对抑郁症状的调控作用及其机制的研究进展
神经退行性疾病发病机制的研究进展
Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer
Tau蛋白介导抑郁症发病及氟西汀治疗的神经可塑性机制研究
阿托伐他汀提高c-kit(+)心肌干细胞治疗急性心肌梗死的疗效及其机制
初探他汀通过CXCR4通路调控炎症反应与血管生成治疗慢性硬膜下血肿及其分子机制
新型抗抑郁剂ZY-1408快速起效的5-HT2C受体机制